Described herein are stable solid oral capsule dosage form comprising dabigatran etexilate or pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient, wherein said dosage form has controlled and reduced levels of N-nitroso dabigatran (NDAB). Also, disclosed are methods of manufacturing such stable solid capsule oral dosage forms of dabigatran etexilate and its pharmaceutically acceptable salt.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
C07D 213/75 - Radicaux amino ou imino, acylés par un acide carboxylique, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p. ex. des carbamates
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 233/90 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
2.
CONTAINER SYSTEM AND PHARMACEUTICAL FOAM COMPOSITION COMPRISING BETAMETHASONE
The present invention relates to a pharmaceutical foam composition comprising a corticosteroid and a Vitamin D analogue for topical administration to a patient in need thereof, such as for the treatment of plaque psoriasis. The present invention also relates to a process for preparing the composition and a suitable container system for administration of the composition. Preferably, the invention relates to the topical administration of betamethasone dipropionate and calcipotriene with one or more pharmaceutically acceptable excipients and propellants where the composition is stable in the container system coated with a coating material selected from the group comprising of epoxyphenol resin, modified polyesters, microflex coating or polyacrylates.
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/593 - Dérivés du 9,10-séco-cholestane, p. ex. cholécalciférol, vitamine D3
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61M 35/00 - Dispositifs pour appliquer des agents, p. ex. des remèdes, sur le corps humain
3.
METERED DOSE INHALERS OF FLUTICASONE OR AN ESTER THEREOF
The invention relates to metered dose inhaler comprising a stable pharmaceutical composition of fluticasone or its pharmaceutically acceptable ester contained in a canister fitted with a metering valve, an actuator and dose counter. The invention also relates to a process for preparing said pharmaceutical composition and its use in the treatment of respiratory disorders such as asthma in a subject (e.g., a human).
The present invention is directed to compound of formula (I), stereoisomer thereof or pharmaceutically acceptable salts thereof, which are useful as IRAK-M degraders, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by IRAK-M.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 209/02 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle
C07D 243/06 - Composés hétérocycliques contenant des cycles à sept chaînons comportant deux atomes d'azote comme uniques hétéro-atomes du cycle les atomes d'azote étant en positions 1, 4
C07D 239/02 - Composés hétérocycliques contenant des cycles diazine-1, 3 ou diazine-1, 3 hydrogéné non condensés avec d'autres cycles
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
5.
SUBSTITUTED BIPHENYL COMPOUNDS AS CBL-B INHIBITORS
The present invention is directed to compound of formula (IA), stereoisomers thereof or pharmaceutically acceptable salts thereof, which are useful as CBL-b inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by CBL-b.
C07D 213/02 - Composés hétérocycliques contenant des cycles à six chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle et avec au moins trois doubles liaisons entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques comportant trois liaisons doubles
C07D 231/02 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles
C07D 233/54 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07D 249/02 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant trois atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as CBL-b inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by CBL-b.
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/4412 - Pyridines non condenséesLeurs dérivés hydrogénés ayant des groupes oxo liés directement à l'hétérocycle
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
9.
SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS
The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as CBL-b inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by CBL-b.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Skin soaps; shampoos; sunscreen for cosmetic use; perfumery; essential oils; body powder; cosmetics; anti-aging creams; hair lotion; skin creams; skin moisturizing gels; non-medicated soaps for face; moisturizing body lotions; non-medicated mouthwashes Pharmaceutical preparations for human use for the treatment of respiratory disorders; nasal spray preparations; Opium alkaloid preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical antitussive-cold preparations; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for skin care; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for wounds; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, anticoagulants; pharmaceutical products and preparations against dry skin caused by pregnancy; pharmaceutical products and preparations for chloasma; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products for ophthalmological use; pharmaceutical products for skin care for animals; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of joint disease; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical skin lotions; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals, namely, anti-infectives; pharmaceuticals, namely, antihelmintics; pharmaceuticals, namely, inducers of erections; pharmaceuticals, namely, lipid lowering agents; preparation for the relief of pain; preparations for the treatment of asthma Spirometer; inhalers for therapeutic use, sold empty; chambers for inhalers; nebulizers for medical purposes; diagnostic apparatus for medical purposes, namely, medical diagnostic apparatus for testing DNA and RNA samples Scientific research for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; scientific and technological services, namely, scientific research, analysis, testing in the field of oncology, immunology and pain management; medical research in the fields of oncology, immunology and pain management; clinical research in the fields of oncology, immunology and pain management; scientific research and development; pharmaceutical drug development services; pharmaceutical research and development; research and development for new products for others; scientific and technological services, namely, scientific research and analysis in the field of chemicals, pharmaceutical preparations, dietetic preparations, demo-cosmetic preparations, and biotechnology; design and testing for new product development; medical research; scientific research in the fields of chemistry, biotechnology and pharmacology; medical and pharmaceutical research services; scientific research services for medical purposes, namely, bacteriological research services; biomedical research services; laboratory research services in the field of cancer treatment, oncology, immunology and pain management; medical and scientific research, namely, conducting clinical trials for others; scientific research in the field of pharmacology; medical research services conducted in a laboratory; scientific and technological services, namely, scientific research and analysis, in the fields of medicine, health, fitness, exercise and wellness; consulting services in the field of pharmaceutical research and development, namely, consultation and collaboration with industry and academic professionals for the identification, research and development of new manufacturing technologies in the field of pharmaceuticals Providing information in the field of medicine and health; medical services; medical assistance services; hygiene care for human beings being health care services; medical clinic services; providing medical information to patients for better lifestyle management to handle the treatment of side effects in the course of treatment of cancer, pain management, skin care, management of diabetes, management of asthma, Chronic Obstructive Pulmonary Disease (COPD) and respiratory diseases
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
16 - Papier, carton et produits en ces matières
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Advertising; business management, organization and administration services in the medical field; provision of information and advisory services relating to e-commerce in the medical field; commercial business management; business administration; promoting public awareness of health and medicine through the provision of a public awareness program in the medical field and various health conditions, diseases and illnesses prevention; promoting public awareness of the need for treatment and management of human diseases and disorders by conducting patient screening programs; promoting collaboration within the scientific, research and medical communities to achieve advances in the medical field; promoting the exchange of information and resources within the scientific research and medical communities to achieve advances in the medical field; collection of information, particularly commercial, scientific and health information, namely, compilation of scientific, health, medical and pharmacology information into computer databases; compiling business, scientific and health data for business purposes; providing an on-line searchable database featuring business information in the fields of medicine, pharmaceuticals and life sciences; arranging subscriptions to information media for others; collection and systematization of scientific, health, medical and pharmacology information in computer databases; advice regarding communication being public relations advice in the fields of health, medicine, pharmacology and the treatment of illnesses; demonstration of goods for promotional or advertising purposes in the fields of health, medicine, pharmacology and the treatment of illnesses; providing consumer product information via the internet, namely, provision of consumer information and advice regarding the selection of products and items to be purchased in the fields of health, medicine, pharmacology and the treatment of illnesses; management of files and records, namely, computerized file management, related to the health status of individuals, drug molecules for medical use and pharmaceutical formulations for medical use, as well as computerized file management related to medicines and medical research; provision of information relating to data processing services of health and medical data; negotiation and conclusion of commercial transactions for others; organization of business meetings, namely, business meeting planning, particularly, with a view to establishing commercial collaborations in the health and medical fields; statistical information compilation services of health and medical information for business purposes; campaign for patient support program, namely, promoting public awareness for patients with cancer, pain management, skin care, management of diabetes, management of asthma, chronic obstructive pulmonary disease (copd) and respiratory diseases Skin soaps; shampoos; sunscreen for cosmetic use; perfumery; essential oils; body powder; cosmetics; anti-aging creams; hair lotion; skin creams; skin moisturizing gels; non-medicated soaps for face; moisturizing body lotions; non-medicated mouthwashes Pharmaceutical preparations for human use for the treatment of respiratory disorders; nasal spray preparations; Opium alkaloid preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical antitussive-cold preparations; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for skin care; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for wounds; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, anticoagulants; pharmaceutical products and preparations against dry skin caused by pregnancy; pharmaceutical products and preparations for chloasma; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products for ophthalmological use; pharmaceutical products for skin care for animals; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of joint disease; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical skin lotions; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals, namely, anti-infectives; pharmaceuticals, namely, antihelmintics; pharmaceuticals, namely, inducers of erections; pharmaceuticals, namely, lipid lowering agents; preparation for the relief of pain; preparations for the treatment of asthma Spirometer; inhalers for therapeutic use, sold empty; chambers for inhalers; nebulizers for medical purposes; diagnostic apparatus for medical purposes, namely, medical diagnostic apparatus for testing DNA and RNA samples Printed materials, namely, brochures, booklets, newsletters and pamphlets featuring health information; Printed matter, namely, promotional and informational materials in the nature of brochures, pamphlets, newsletters, and stationery relating to pharmaceutical and research company, pharmaceuticals products, studies, publications, visual aids, leaflet before literature, patient information leaflet, and material on the treatment and prevention of diseases; Printed educational materials in the fields of nutrition, dietary management, dysphagia, wound care and malnutrition Scientific research for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; scientific and technological services, namely, scientific research, analysis, testing in the field of oncology, immunology and pain management; medical research in the fields of oncology, immunology and pain management; clinical research in the fields of oncology, immunology and pain management; scientific research and development; pharmaceutical drug development services; pharmaceutical research and development; research and development for new products for others; scientific and technological services, namely, scientific research and analysis in the field of chemicals, pharmaceutical preparations, dietetic preparations, demo-cosmetic preparations, and biotechnology; design and testing for new product development; medical research; scientific research in the fields of chemistry, biotechnology and pharmacology; medical and pharmaceutical research services; scientific research services for medical purposes, namely, bacteriological research services; biomedical research services; laboratory research services in the field of cancer treatment, oncology, immunology and pain management; medical and scientific research, namely, conducting clinical trials for others; scientific research in the field of pharmacology; medical research services conducted in a laboratory; scientific and technological services, namely, scientific research and analysis, in the fields of medicine, health, fitness, exercise and wellness; consulting services in the field of pharmaceutical research and development, namely, consultation and collaboration with industry and academic professionals for the identification, research and development of new manufacturing technologies in the field of pharmaceuticals Providing information in the field of medicine and health; medical services; medical assistance services; hygiene care for human beings being health care services; medical clinic services; providing medical information to patients for better lifestyle management to handle the treatment of side effects in the course of treatment of cancer, pain management, skin care, management of diabetes, management of asthma, Chronic Obstructive Pulmonary Disease (COPD) and respiratory diseases
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
16 - Papier, carton et produits en ces matières
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Advertising; business management, organization and administration services in the medical field; provision of information and advisory services relating to e-commerce in the medical field; commercial business management; business administration; promoting public awareness of health and medicine through the provision of a public awareness program in the medical field and various health conditions, diseases and illnesses prevention; promoting public awareness of the need for treatment and management of human diseases and disorders by conducting patient screening programs; promoting collaboration within the scientific, research and medical communities to achieve advances in the medical field; promoting the exchange of information and resources within the scientific research and medical communities to achieve advances in the medical field; collection of information, particularly commercial, scientific and health information, namely, compilation of scientific, health, medical and pharmacology information into computer databases; compiling business, scientific and health data for business purposes; providing an on-line searchable database featuring business information in the fields of medicine, pharmaceuticals and life sciences; arranging subscriptions to information media for others; collection and systematization of scientific, health, medical and pharmacology information in computer databases; advice regarding communication being public relations advice in the fields of health, medicine, pharmacology and the treatment of illnesses; demonstration of goods for promotional or advertising purposes in the fields of health, medicine, pharmacology and the treatment of illnesses; providing consumer product information via the internet, namely, provision of consumer information and advice regarding the selection of products and items to be purchased in the fields of health, medicine, pharmacology and the treatment of illnesses; management of files and records, namely, computerized file management, related to the health status of individuals, drug molecules for medical use and pharmaceutical formulations for medical use, as well as computerized file management related to medicines and medical research; provision of information relating to data processing services of health and medical data; negotiation and conclusion of commercial transactions for others; organization of business meetings, namely, business meeting planning, particularly, with a view to establishing commercial collaborations in the health and medical fields; statistical information compilation services of health and medical information for business purposes; campaign for patient support program, namely, promoting public awareness for patients with cancer, pain management, skin care, management of diabetes, management of asthma, chronic obstructive pulmonary disease (copd) and respiratory diseases Skin soaps; shampoos; sunscreen for cosmetic use; perfumery; essential oils; body powder; cosmetics; anti-aging creams; hair lotion; skin creams; skin moisturizing gels; non-medicated soaps for face; moisturizing body lotions; non-medicated mouthwashes Pharmaceutical preparations for human use for the treatment of respiratory disorders; nasal spray preparations; Opium alkaloid preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical antitussive-cold preparations; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for skin care; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for wounds; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, anticoagulants; pharmaceutical products and preparations against dry skin caused by pregnancy; pharmaceutical products and preparations for chloasma; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products for ophthalmological use; pharmaceutical products for skin care for animals; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of joint disease; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical skin lotions; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals, namely, anti-infectives; pharmaceuticals, namely, antihelmintics; pharmaceuticals, namely, inducers of erections; pharmaceuticals, namely, lipid lowering agents; preparation for the relief of pain; preparations for the treatment of asthma Spirometer; inhalers for therapeutic use, sold empty; chambers for inhalers; nebulizers for medical purposes; diagnostic apparatus for medical purposes, namely, medical diagnostic apparatus for testing DNA and RNA samples Printed materials, namely, brochures, booklets, newsletters and pamphlets featuring health information; Printed matter, namely, promotional and informational materials in the nature of brochures, pamphlets, newsletters, and stationery relating to pharmaceutical and research company, pharmaceuticals products, studies, publications, visual aids, leaflet before literature, patient information leaflet, and material on the treatment and prevention of diseases; Printed educational materials in the fields of nutrition, dietary management, dysphagia, wound care and malnutrition Scientific research for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; scientific and technological services, namely, scientific research, analysis, testing in the field of oncology, immunology and pain management; medical research in the fields of oncology, immunology and pain management; clinical research in the fields of oncology, immunology and pain management; scientific research and development; pharmaceutical drug development services; pharmaceutical research and development; research and development for new products for others; scientific and technological services, namely, scientific research and analysis in the field of chemicals, pharmaceutical preparations, dietetic preparations, demo-cosmetic preparations, and biotechnology; design and testing for new product development; medical research; scientific research in the fields of chemistry, biotechnology and pharmacology; medical and pharmaceutical research services; scientific research services for medical purposes, namely, bacteriological research services; biomedical research services; laboratory research services in the field of cancer treatment, oncology, immunology and pain management; medical and scientific research, namely, conducting clinical trials for others; scientific research in the field of pharmacology; medical research services conducted in a laboratory; scientific and technological services, namely, scientific research and analysis, in the fields of medicine, health, fitness, exercise and wellness; consulting services in the field of pharmaceutical research and development, namely, consultation and collaboration with industry and academic professionals for the identification, research and development of new manufacturing technologies in the field of pharmaceuticals Providing information in the field of medicine and health; medical services; medical assistance services; hygiene care for human beings being health care services; medical clinic services; providing medical information to patients for better lifestyle management to handle the treatment of side effects in the course of treatment of cancer, pain management, skin care, management of diabetes, management of asthma, Chronic Obstructive Pulmonary Disease (COPD) and respiratory diseases
13.
PHARMACUTICAL COMPOSITION COMPRISING REMOGLIFLOZIN ETABONATE, METFORMIN HYDROCHLORIDE AND VILDAGLIPTIN
The present invention relates to pharmaceutical composition comprising Remogliflozin or pharmaceutically acceptable salt, ester or derivatives thereof in combination with one or more anti-hyperglycemic agent. In particular, the present invention relates to pharmaceutical composition comprising combination of Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin for the treatment of diabetes mellitus and its method of manufacturing thereof.
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
The invention relates to a stable solid oral pharmaceutical composition comprising itraconazole which provides reduction in pill burden in the treatment of fungal infections, including superficial infections, such as onychomycosis, as well as systemic fungal infections, for example, pulmonary or extrapulmonary blastomycosis, histoplasmosis, and aspergillosis. The application also relates to a process for preparing the pharmaceutical composition comprising itraconazole.
The invention relates to a lyophilized pharmaceutical composition comprising Selexipag or pharmaceutically acceptable salt thereof. The composition of the present invention further comprises pharmaceutically acceptable excipients and optionally contains buffer. The invention further relates to a process of preparing the said composition which may be used for the treatment of various diseases or disorders.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
16.
METERED DOSE INHALERS OF FLUTICASONE OR AN ESTER THEREOF
The invention relates to metered dose inhaler comprising a stable pharmaceutical composition of fluticasone or its pharmaceutically acceptable ester contained in a canister fitted with a metering valve, an actuator and dose counter. The invention also relates to a process for preparing said pharmaceutical composition and its use in the treatment of respiratory disorders such as asthma in a subject (e.g., a human).
The present disclosure relates to the field of portable self-screening devices for determining lung capacity. The invention relates to easy to use portable device for screening of respiratory disorders such as asthma and/or chronic obstructive pulmonary disease.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
35 - Publicité; Affaires commerciales
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Chemical substances, chemical materials and chemical preparations, and natural elements. Cosmetics; toiletries; soaps; shampoo; skincare; anti-aging creams; hair care; hair lotion; sunscreen for cosmetic use; perfumery; essential oils; body powder; hand creams; moisturiser lotions; body lotions; cosmetic skin care preparations; skin creams; skin gels' skin moisturizing gel; face wash; face wash cream, facial cleansers, facial treatment washes being non-medicated soaps; non-medicated dentifrices; non-medicated mouthwashes. Pharmaceuticals; pharmaceutical and medical preparations; medicinal preparations and substances for human use; preparations for therapeutic or medical preparations; pharmaceutical preparations for human use for the treatment of respiratory disorders; nasal spray preparations; medical and pharmaceutical preparations, namely, inhaler preparations for treatment of Chronic Obstructive Pulmonary Disease (COPD); opium alkaloid preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical antitussive-cold preparations; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for skin care; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, and for the treatment of inflammatory disorders, and for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy; pharmaceutical and biological preparations for the treatment of cancer; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for wounds; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, anticoagulants; pharmaceutical products and preparations against dry skin caused by pregnancy; medicated skin care preparations; medicated skin care preparations, namely, gels; pharmaceutical products and preparations for chloasma; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products for ophthalmological use; pharmaceutical products for skin care for animals; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of joint disease; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical skin lotions; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals, namely, anti-infectives; pharmaceuticals, namely, antihelmintics; pharmaceuticals, namely, inducers of erections; pharmaceuticals, namely, lipid lowering agents; preparation for the relief of pain; preparations for the treatment of asthma; preparations for therapeutic or medical purposes, namely therapeutic medicated skin preparations for treatment of skin diseases; decongestant nasal sprays. Medical apparatus and instruments; spirometers; medical devices; medical devices namely auto analysers; nasal spray; inhaler; inhalers sold empty; nebulizer; diagnostic apparatus for medical purposes; chromatographic medical diagnostic apparatus. Advertising services; advertising services namely promoting patient support programs and public awareness of patients with cancer, pain management, skin care, management of diabetes, management of asthma, Chronic Obstructive Pulmonary Disease (COPD) and respiratory diseases. Educational services; educational services namely providing workshops and seminars in the fields of cancer treatment, oncology, immunology and pain management; publication of journals featuring research articles and clinical trials for pharmaceutical preparations; education services namely conducting online instruction and courses in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments; providing of training; provision of educational content namely providing on-line instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments; training in the use and operation of medical devices, medical imaging apparatus and medical research apparatus and consultation relating thereto; educational services, namely, conducting live and online seminars, classes, workshops, lectures, panel discussions, and training programs in the field of pharmaceutical products, healthcare and medical diseases, disorders and related treatments; educational services namely providing non-downloadable webinars in the field of health and medical information and distribution of course material in connection therewith; education services, namely, developing, arranging and conducting educational programs and providing courses of instruction in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine; providing training programs and developing training programs relating to the use and operation of medical devices, medical research apparatus and consultation relating thereto; providing online publications namely instructional materials in the nature of worksheets and textbooks, featuring study materials in the field of pharmaceutical products, healthcare and medical disease, disorders and related treatments; conducting educational seminars in the fields of healthcare, the use of pharmaceuticals, and medical devices, medical research, surgery, medical science and medicine. Medical and pharmaceutical research services; medical and scientific research services; scientific research for medical purposes in the field of oncology, pain management, dermatology, diabetology, respiratory diseases, biosimilars; scientific research services for medical purposes including and not limited to bacteriological research services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; scientific and technological services namely scientific research and analysis; testing in the field of oncology, immunology and pain management; medical research in the fields of oncology, immunology and pain management; clinical research in the fields of oncology, immunology and pain management; scientific research and development; pharmaceutical drug development services; pharmaceutical research and development; research and development for new products for others; chemical, pharmaceutical, nutraceuticals and nutritional science, dermo-cosmetic and biotechnology analysis and research; design and testing for new product development; diagnostic product testing and analysis, namely medical research and product research for industrial uses; scientific research in the fields of chemistry, biotechnology and pharmacology; medical and pharmaceutical research services; biomedical research services; laboratory research services; clinical trial services; pharmacological research services; medical research laboratory services; and scientific and technological services and research and design relating thereto. Licensing of patents, trademarks and intellectual property.
19.
CONTAINER SYSTEM AND PHARMACEUTICAL FOAM COMPOSITION COMPRISING BETAMETHASONE
The present invention relates to a pharmaceutical foam composition comprising a corticosteroid and a Vitamin D analogue for topical administration to a patient in need thereof, such as for the treatment of plaque psoriasis. The present invention also relates to a process for preparing the composition and a suitable container system for administration of the composition. Preferably, the invention relates to the topical administration of betamethasone dipropionate and calcipotriene with one or more pharmaceutically acceptable excipients and propellants where the composition is stable in the container system coated with a coating material selected from the group comprising of epoxyphenol resin, modified polyesters, microflex coating or polyacrylates.
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/593 - Dérivés du 9,10-séco-cholestane, p. ex. cholécalciférol, vitamine D3
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61F 13/40 - Garnitures absorbantes, p. ex. serviettes ou tampons hygiéniques pour application externe ou interne au corpsMoyens pour les maintenir en place ou les fixerApplicateurs de tampons comportant des moyens incorporés pour délivrer une substance au matériau absorbant, p. ex. contenue dans un récipient brisable
20.
PHARMACEUTICAL COMPOSITION COMPRISING REMOGLIFLOZIN OR SALT OR ESTER THEREOF AND TENELIGLIPTIN OR SALT THEREOF
The invention relates to a fixed dose combination of remogliflozin or pharmaceutically acceptable salt or ester thereof and DPP-IV inhibitor or pharmaceutically acceptable salt thereof. In particular, a fixed dose combination of remogliflozin or pharmaceutically acceptable salt or ester thereof and teneligliptin or pharmaceutically acceptable salt thereof. This fixed dosed combination is suitable for twice a day administration. More preferably, there is provided a pharmaceutical composition comprising a fixed dose combination of remogliflozin etabonate and teneligliptin hydrobromide or oxalate salt.
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
21.
STABLE AEROSOL COMPOSITION FOR INHALATION COMPRISING GLYCOPYRRONIUM, FORMOTEROL AND CORTICOSTEROID
The present invention relates to a stable aerosol composition for inhalation administration using metered dose inhaler (MDI) comprising glycopyrronium or its pharmaceutically acceptable salt, formoterol or its pharmaceutically acceptable salt, a corticosteroid selected from fluticasone, budesonide, beclomethasone and its pharmaceutically acceptable salt or esters thereof, HFA propellant and one or more other pharmaceutically acceptable excipients. Particularly, the present invention relates to a suspension aerosol composition comprising glycopyrronium bromide, formoterol fumarate dihydrate and fluticasone propionate, co-solvent, optionally a stabilizer and HFA propellant wherein all the active ingredients are solely present in respirable suspended form in the composition. The present invention also relates to process for preparing such composition and its use for the treatment of respiratory disorders such as asthma and/or chronic obstructive pulmonary disease in a subject in need thereof.
The present invention relates to an inhalable fixed dose dry powder composition comprising glycopyrronium or its pharmaceutically acceptable salt, formoterol or its pharmaceutically acceptable salt and fluticasone, or a pharmaceutically acceptable salt or ester thereof, such as fluticasone propionate. Preferably, the present invention relates to an inhalable dry powder composition comprising an effective amounts of glycopyrronium or its pharmaceutically acceptable salt, formoterol or its pharmaceutically acceptable salt, fluticasone propionate and lactose. The present invention also relates to a process of preparing such compositions and to their use in the treatment of respiratory diseases in a subject in need thereof by inhalation administration of such dry powder compositions.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/568 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone
A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
The present disclosure relates to the field of medical devices and discloses a medicament dispensing device (100) comprising an actuator body (102), a medicament canister (108), a dispensing valve (112), a dose counter, a shake switch (302), and a display unit (106). The canister (108) stores a medicament under pressure. The dispensing valve (112) discharges a dose of the medicament from the medicament canister (108) into an outlet (110) when a user depresses the canister (108). The dose counter maintains a count of total number of medicament doses dispensed from the canister (108). The switch (302) detects shaking of the canister (108) and generates an activation signal when shaking of the canister (108) is detected for a pre-defined number of times. The display unit (106) displays number of medicament doses left in the canister (108) or number of consumed medicament doses, upon receiving the activation signal from the switch (302).
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
24.
STABLE AEROSOL COMPOSITION FOR INHALATION COMPRISING GLYCOPYRRONIUM
The present invention relates to a stable suspension aerosol composition for inhalation comprising glycopyrronium or its pharmaceutical acceptable salt, HFA propellant and one or more pharmaceutically acceptable excipients, to be delivered by pressurized metered dose inhalers (MDIs) for pulmonary administration. The present aerosol composition for inhalation may further optionally comprises of one or more additional active agents like β-agonist. The present invention provides a suspension aerosol composition wherein active ingredients selected from glycopyrronium or its pharmaceutical acceptable salt and/or formoterol or its pharmaceutically acceptable salt are solely present in respirable suspended form. The aerosol composition of present invention is free of respirable suspended particles of phospholipid, lipids, carbohydrate, amino acid, organic and inorganic salts. Further, the present invention also relates to process of preparing the suspension aerosol composition and use of such composition for the treatment of respiratory disorders such as asthma and/or chronic obstructive pulmonary disease in a subject in need thereof.
The present invention relates to an inhalable dry powder composition comprising an effective amount of glycopyrronium or its pharmaceutically acceptable salt; an effective amount of indacaterol or its pharmaceutically acceptable salt; an effective amount of fluticasone or its pharmaceutically acceptable esters and a diluent, wherein said composition is free from a hydrophobic excipient, their process of preparation and method of administering for the treatment of respiratory disorders in a subject. Further the invention is an inhalable dry powder composition comprising an effective amount of co micronized premix consisting of Glycopyronnium bromide and lactose; an effective amount of Indacaterol hydrochloride; an effective amount of fluticasone propionate and lactose, wherein said composition is free from a hydrophobic excipients.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
A61K 31/568 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
26.
A PHARMACEUTICAL COMPOSITION OF GABAPENTIN ENACARBIL OR SALT THEREOF
The present invention provides a stable pharmaceutical compositions comprising gabapentin enacarbil or pharmaceutically acceptable salts thereof and the process of preparation thereof. The invention also relates to the use of said pharmaceutical compositions for the treatment of restless legs syndrome or post herpetic neuralgia
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
The present invention relates to a stable aerosol inhalation compositions to be used with pressurized metered dose inhalers (pMDI) comprising formoterol or its pharmaceutically acceptable salts, optionally in combination with beclomethasone or its pharmaceutically acceptable salt as active ingredients, an alcoholic co-solvent, an organic acid and an environmentally safe hydrofluoroalkane (HFA) as a propellant, their process of preparation and method of administering for the treatment of respiratory disorders in a subject.
A61K 9/72 - Préparations médicinales caractérisées par un aspect particulier à fumer ou inhaler
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
The invention relates to a combination of remogliflozin or salt or ester thereof and DPP-IV inhibitor or salt thereof. In particular, the invention relates to a fixed dose pharmaceutical composition comprising a combination of remogliflozin or salt or ester thereof and DPP-IV inhibitor or salt thereof. Disclosed is the invention relates to a fixed dose pharmaceutical composition comprising a combination of remogliflozin or salt or ester thereof and vildagliptin or salt thereof; wherein the combination produces synergistic effect in reducing blood glucose levels in patients with diabetes. Also disclosed process of preparing pharmaceutical composition thereof.
A61K 9/24 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue en doses unitaires constituées de couches ou feuilletées
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
29.
PHARMACEUTICAL COMPOSITION COMPRISING OF REMOGLIFLOZIN OR SALT OR ESTER THEREOF AND VILDAGLIPTIN OR SALT THEREOF
The invention relates to a stable pharmaceutical composition comprising remogliflozin or salt or ester thereof, and vildagliptin or salt thereof. In particular disclosed is a pharmaceutical composition comprising a first portion and a second portion, wherein said first portion comprises granules of remogliflozin or salt or ester thereof and a pharmaceutically acceptable excipient, said second portion comprises granules of vildagliptin or salt thereof and a pharmaceutically acceptable excipient; wherein granules of remogliflozin or salt or ester thereof are preapred by wet granulation and granules of vildagliptin or salt thereof are prepared by roller compaction; wherein said portions are compressed together to obtain a bilayer tablet dosage form which is coated with non-aquous seal coat.
A61K 9/24 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue en doses unitaires constituées de couches ou feuilletées
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
30.
CONTAINER SYSTEM AND PHARMACEUTICAL FOAM COMPOSITION COMPRISING BETAMETHASONE
The present invention relates to a pharmaceutical foam composition comprising a corticosteroid and a Vitamin D analogue for topical administration to a patient in need thereof, such as for the treatment of plaque psoriasis. The present invention also relates to a process for preparing the composition and a suitable container system for administration of the composition. Preferably, the invention relates to the topical administration of betamethasone dipropionate and calcipotriene with one or more pharmaceutically acceptable excipients and propellants where the composition is stable in the container system coated with a coating material selected from the group comprising of epoxyphenol resin, modified polyesters, microflex coating or polyacrylates.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
The present invention provides a stable pharmaceutical composition of axitinib or salt thereof. There is also provided process of preparation of such composition. In particular there is provided stable pharmaceutical composition comprising a therapeutically effective amount of axitinib or salt thereof, calcium phosphate and pharmaceutical acceptable excipients. Further, there is provided a stable pharmaceutical composition comprising a therapeutically effective amount of axitinib or salt thereof, calcium phosphate and pharmaceutical acceptable excipients and wherein the composition is free of crystalline form XLI.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
The present invention relates to an improved process for the preparation of Remogliflozin, Remogliflozin etabonate or pharmaceutically acceptable salt, solvate, hydrate thereof. The present invention relates to an improved process for preparation of Remogliflozin etabonate or pharmaceutically acceptable salt, solvate, hydrate thereof through formation of isopropyl alcohol solvate of remogliflozin etabonate.
maxmax) of remogliflozin or pharmaceutically acceptable salt or ester thereof between about 300ng/ml to about 1400ng/ml or the composition provides an AUC of remogliflozin or pharmaceutically acceptable salt or ester thereof between about 700ng.hr/ml to about 6000ng.h/ml.
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 9/24 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue en doses unitaires constituées de couches ou feuilletées
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
34.
PHARMACUTICAL COMPOSITION COMPRISING REMOGLIFLOZIN AND ANTIDIABETIC AGENT
The invention relates to a pharmaceutical composition comprising remogliflozin or pharmaceutically acceptable salt or ester thereof, and metformin or pharmaceutically acceptable salt thereof. In particular, it relates to an immediate release pharmaceutical composition comprising: (a) remogliflozin or pharmaceutically acceptable salt or ester thereof, (b) metformin or pharmaceutically acceptable salt thereof, and (c) a pharmaceutically acceptable excipient.
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
The present invention relates to a process for the preparation of brivaracetam and salts thereof. The present invention provides process for the preparation of brivaracetam and salts thereof with high chiral purity. The present invention provides process for the preparation of brivaracetam and salts thereof wherein the amount of other stereoisomers of brivaracetam is low.
A topical pharmaceutical composition comprises adapalene or a pharmaceutical acceptable salt thereof and minocycline or a pharmaceutical acceptable salt thereof. The composition is for topical application and used to treat acne.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
The present invention relates to a process for the preparation of lifitegrast, a compound of formula I, the process comprising deprotecting a compound of formula III using a Lewis acid. The present invention also relates to lifitegrast organic amine salt, a compound of formula II, process for its preparation and conversion thereof to lifitegrast.
C07D 217/06 - Composés hétérocycliques contenant les systèmes cycliques de l'isoquinoléine ou de l'isoquinoléine hydrogénée avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle contenant l'azoteAlkylène-bis-isoquinoléines avec l'atome d'azote du cycle acylé par des acides carboxyliques, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p. ex. des carbamates
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
The present invention relates to a process for the preparation of nintedanib or salt thereof. The process comprising reacting compound of formula VI with acetic anhydride and triethyl ortho benzoate to obtain a compound of formula V; further reacting the compound of formula V with the compound of formula IV to obtain nintedanib the compound of formula I. The present invention also relates to a process to obtain crystalline compound of formula V.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections; Pharmaceutical preparations for the prevention and treatment of malaria; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, namely, epilepsy and migraine headaches; Pharmaceutical preparations for the relief of pain
(2) Pharmaceutical preparations for the prevention and treatment of disorders of the cardio-vascular system; pharmaceutical preparations for the treatment of respiratory disorders
The present invention relates to a process for the preparation of crisaborole, the process comprising reacting a compound of formula IIa with a compound of formula III to give a compound of formula IV and converting the compound of formula IV to crisaborole. The present invention also relates to a process for the preparation of crystalline crisaborole.
The present invention provides a process for preparation of deoxycholic acid or salt thereof; the process comprises the steps of reacting the compound of formula II to obtain a compound of formula III; the compound of formula III is converted to a compound of formula IV and the compound of formula IV is converted to deoxycholic acid. The present invention also provides a process for the purification of deoxycholic acid or salt thereof.
The present invention relates to an improved process for the preparation of fosaprepitant or salt thereof. More particularly, the present invention relates to an effective process for the preparation of fosaprepitant dibenzylester, a compound of Formula II, which is a useful intermediate in the preparation of fosaprepitant or fosaprepitant dimeglumine.
C07F 9/00 - Composés contenant des éléments des groupes 5 ou 15 du tableau périodique
C07F 9/6568 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle comportant des atomes de phosphore, avec ou sans atomes d'azote, d'oxygène, de soufre, de sélénium ou de tellure, comme hétéro-atomes du cycle comportant des atomes de phosphore comme uniques hétéro-atomes du cycle
The present invention relates to an immediate release oral formulation of remogliflozin or pharmaceutically acceptable salts thereof administered in patients in need thereof, for the treatment of diabetes mellitus. The present invention further relates to a pharmaceutical formulation comprising synergistic combination of remogliflozin etabonate and metformin hydrochloride. In a preferred embodiment, the invention relates to a bilayer tablet comprising an immediate release layer and an extended release layer wherein the immediate release layer comprises remogliflozin etabonate or pharmaceutically acceptable salts thereof and the extended release layer comprises metformin or pharmaceutically acceptable salt thereof.
The present invention provides oxalate salts of teneligliptin and solvates thereof exhibiting superior physiochemical properties. In particular, crystalline form of teneligliptin 2.5 oxalate 1.0 hydrate and crystalline form of teneligliptin 3.0 oxalate 1.0 hydrate are disclosed. Also provided are methods of preparing the same, and uses thereof.
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
45.
FORMULATIONS COMPRISING OXALATE SALTS OF TENELIGLIPTIN AND SOLVATES THEREOF
The present invention relates to pharmaceutically acceptable formulations comprising oxalate salts of Teneligliptin and solvates thereof. Also provided are combinations with biguanides and use of said pharmaceutically acceptable formulations for the management of glucose metabolism disorders.
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceutical preparations, namely, products for the treatment of respiratory diseases. Pharmaceutical and medicinal devices and products for the treatment of respiratory diseases.
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
The present invention relates to stable topical compositions comprising Luliconazole. Further the present invention also relates to stable topical compositions comprising combination of luliconazole with a corticosteroid such as betamethasone or clobetasol. The compositions are free of an aliphatic alcohol and a ketone.
C07D 409/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to a process for the preparation of ledipasvir a compound of formula I, which is useful as an antiviral agent. The present invention also provides ledipasvir phosphate.
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
The present invention relates to process for preparation of tavaborole with high purity. The present invention relates to method of assessing the purity of tavaborole.
The present invention relates to an inhalable fixed dose powder composition comprising glycopyrronium or its pharmaceutically acceptable salt and formoterol or its pharmaceutically acceptable salt. Preferably, the present invention relates to an inhalable powder composition comprising effective amounts of glycopyrronium or its pharmaceutically acceptable salt, formoterol or its pharmaceutically acceptable salt, and lactose; and; a process of preparing such composition and its use in the treatment of respiratory disorders.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
The present invention relates to a process for the preparation of amorphous lumacaftor. The present invention relates to a process for the preparation of intermediate 6-amino-2- halo-3-methylpyridine compounds used in the preparation of lumacaftor. The present invention relates to lumacaftor hydrobromide, process for its preparation and conversion thereof to lumacaftor.
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
The present invention relates to a process for preparation of apremilast. The present invention relates to p-xylene solvate of apremilast and process for its preparation.
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
The present invention relates to a process for the preparation of amorphous dapagliflozin. The present invention relates to 2,3-butanediol solvate of dapagliflozin and process for its preparation.
A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Opium alkaloid preparations for the treatment of chronic pain; Pharmaceutical anti-allergic preparations; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, spinal cord diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases and intermittent claudication; Pharmaceutical preparations for the treatment of gastro-intestinal diseases including diarrhea; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for skin care, namely, creams, gels, lotions, body washes, antibiotic creams and ointments for the treatment of dry skin, Psoriasis, eczema, acne and allergies; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease and intermittent claudication; Pharmaceutical preparations for the prevention and treatment of disorders of the immune system, namely, autoimmune diseases and immunologic deficiency syndromes; Pharmaceutical preparations for the prevention and treatment of disorders of the cardio-vascular system; Pharmaceutical preparations for the prevention and treatment of disorders of the metabolic system, namely, diabetes, bulimia nervosa, anorexia, obesity, hypothyroidism and hypoglycemia; Pharmaceutical preparations for the prevention and treatment of disorders of the respiratory system; Pharmaceutical preparations for the prevention and treatment of disorders of the biliary tract; Pharmaceutical preparations for the prevention and treatment of disorders of the musculo-skeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, bone fractures, sprains and cartilage injuries; Pharmaceutical preparations for the prevention and treatment of disorders of the genitourinary system, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; Pharmaceutical preparations for the treatment of inflammatory disorders, namely, inflammation of alimentary canal, bowel diseases and inflammatory connective tissue diseases; Pharmaceutical preparations for use in dermatology, namely, for the treatment of dermatitis, skin pigmentation diseases, eczema, acne and psoriasis; Pharmaceutical preparations for use in oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, namely, bacterial skin infections, bacterial enteritis, pneumonia, respiratory tract infections, infections of the alimentary canal, infections of the eyes, nose, ears and mouth and ulcers; and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections and skin infections; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, a blood clotting aid and a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents, for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations against dry skin caused by pregnancy; Pharmaceutical preparations for chloasma; Pharmaceutical preparations for hydrating the skin during pregnancy; Pharmaceutical preparations for pregnancy blemishes; Pharmaceutical preparations for preventing skin blemishes during pregnancy; Pharmaceutical preparations to prevent stretch marks; Pharmaceutical preparations to prevent swelling in the legs; Pharmaceutical preparations for ophthalmological use; Pharmaceutical preparations for the treatment of dermatitis and skin pigmentation diseases for animals; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for the treatment of joint disease; Pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), and for the treatment of infectious diseases, namely, respiratory infections, eye infections and skin infections; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Preparation for the relief of pain; Preparations for the treatment of asthma.
The present invention relates to a process for the preparation of ospemifene and pharmaceutically acceptable salts thereof which comprises the step of recycling the undesired E-4-(4-hydroxy-1,2-diphenylbut-1-enyl)phenol to generate an isomeric mixture of Z,E-4-(4-hydroxy-1,2-diphenylbut-1-enyl)phenol.
C07C 41/30 - Préparation d'éthers par des réactions ne formant pas de liaisons sur l'oxygène de la fonction éther par augmentation du nombre d'atomes de carbone, p. ex. par oligomérisation
C07C 59/13 - Composés saturés ne comportant qu'un groupe carboxyle et contenant des groupes éther, des groupes , des groupes ou des groupes contenant des cycles
C07C 43/23 - Éthers une liaison sur l'oxygène de la fonction éther étant sur un atome de carbone d'un cycle aromatique à six chaînons contenant des groupes hydroxyle ou O-métal
C07D 409/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
Provided an inhalable pharmaceutical composition comprising glycopyrronium or its salt. Preferably, provided an inhalable pharmaceutical composition comprising an effective amount of glycopyrronium or its salt and lactose; a process of preparing such composition and its use in the treatment of respiratory disorders.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
C07D 333/22 - Radicaux substitués par des hétéro-atomes liés par une liaison double ou par deux hétéro-atomes, autres que des halogènes, liés au même atome de carbone par des liaisons simples
C07D 333/24 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 409/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 333/12 - Radicaux substitués par des atomes d'halogènes ou par des radicaux nitro ou nitroso
C07D 333/20 - Radicaux substitués par des hétéro-atomes, autres que les halogènes, liés par des liaisons simples par des atomes d'azote
The present invention relates to a breath-actuated dry powder inhaler, wherein a breath actuated mechanism comprises a flap (11) movable from a substantially closed position to a substantially open position and a bistable biasing spring (10) holding the flap in the substantially closed position. The breath actuated mechanism is primed by rotation of a mouthpiece cover (17) from a substantially closed to a substantially open position such that on inhalation breath induced low pressure overcomes the bistable biasing spring to allow opening of the flap wherein the bistable spring acts to move the flap to the open. During the flap travel from the closed to the open position, the movement of the flap forces a latch (21) retaining an energized dose opening mechanism to be disengaged, thereby triggering dose opening by the piercer blade (3), wherein the dose opening mechanism is energized by the opening of the mouthpiece cover and is held in a latched position until disengaged by movement of the flap. The piercer blade which cuts a slit in the sealed foil packet moves through a lower foil, the dose pocket and an upper foil.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
16 - Papier, carton et produits en ces matières
35 - Publicité; Affaires commerciales
Produits et services
Pharmaceutical preparations (only for preparations being available under prescription); sanitary preparations for medical purposes (only for preparations being available under prescription); dietetic food and substances adapted for medical use, food for babies; dietary supplements for humans; plasters (excluding plasters for cosmetic purposes), materials for dressings. Paper, cardboard; printed matter; leaflets; bookbinding material; photographs; stationery; letterhead paper; envelopes; adhesives for stationery or household purposes; artists' materials; paint brushes; typewriters and office requisites (except furniture); instructional and teaching material (except apparatus); plastic materials for packaging (not included in other classes); printers' type; printing blocks. Retail or wholesale services for pharmaceutical preparations and medical supplies and import and export of pharmaceutical preparations and not for preparations containing an active pharmaceutical ingredient for body and beauty care or for dermatological preparations unless these are pharmaceutical preparations being available under prescription.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
16 - Papier, carton et produits en ces matières
35 - Publicité; Affaires commerciales
Produits et services
Pharmaceutical preparations (excluding non-prescription medicines); sanitary preparations for medical purposes (only for preparations being available under prescription); dietetic food and substances adapted for medical use, food for babies; dietary supplements for humans; plasters; materials for dressings. Paper, cardboard; printed matter; leaflets; bookbinding material; photographs; stationery; letterhead paper; envelopes; adhesives for stationery or household purposes; artists' materials; paint brushes; typewriters and office requisites (except furniture); instructional and teaching material (except apparatus); plastic materials for packaging (not included in other classes); printers' type; printing blocks. Retail or wholesale services for pharmaceutical preparations and medical supplies and import and export of pharmaceutical preparations, all aforesaid services not for preparations containing an active pharmaceutical ingredient for body and beauty care or for dermatological preparations unless these are pharmaceutical preparations being available under prescription.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
16 - Papier, carton et produits en ces matières
35 - Publicité; Affaires commerciales
Produits et services
Pharmaceutical preparations ( excluding non-prescription medicines); sanitary preparations for medical purposes (only for preparations being available under prescription); dietetic food and substances adapted for medical use; food for babies; dietary supplements for humans; plasters, materials for dressings. Paper, cardboard; printed matter; leaflets; bookbinding material; photographs; stationery; letterhead paper; envelopes; adhesives for stationery or household purposes; artists' materials; paint brushes; typewriters and office requisites (except furniture); instructional and teaching material (except apparatus); plastic materials for packaging (not included in other classes); printers' type; printing blocks. Retail or wholesale services for pharmaceutical preparations and medical supplies and import and export of pharmaceutical preparations, all aforesaid services not for preparations containing an active pharmaceutical ingredient for body and beauty care or for dermatological preparations unless these are pharmaceutical preparations being available under prescription.
71.
TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE
The present patent application relates to a method of treating allergic rhinitis in a subject (preferably a human) by administering a combination of mometasone or its salt and olopatadine or its salt.
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/335 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine
The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
The present invention relates to a fixed dose pharmaceutical composition comprising mometasone and azelastine. Particularly, the present invention provides a stable fixed dose pharmaceutical composition in the form of a nasal spray comprising mometasone or its salt and azelastine or its salt; a process for preparing such composition; and its use in treatment of rhinitis in a subject.
A01N 57/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques du phosphore
A61K 31/67 - Composés du phosphore ayant le soufre comme hétéro-atome d'un cycle
Non-enteric pharmaceutical composition for oral administration comprising crofelemer and a pharmaceutically acceptable excipient is disclosed. The process for preparing such composition and its use in treating secretory diarrhea in a subject are also disclosed.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 36/47 - Euphorbiaceae (famille de l'euphorbe), p. ex. Ricinus (ricin)
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Opium alkaloid preparations for the treatment of chronic pain; Pharmaceutical anti-allergic preparations; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, spinal cord diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases and intermittent claudication; Pharmaceutical preparations for the treatment of gastro-intestinal diseases including diarrhea; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for skin care, namely, creams, gels, lotions, body washes, antibiotic creams and ointments for the treatment of dry skin, Psoriasis, eczema, acne and allergies; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease and intermittent claudication; Pharmaceutical preparations for the prevention and treatment of disorders of the immune system, namely, autoimmune diseases and immunologic deficiency syndromes; Pharmaceutical preparations for the prevention and treatment of disorders of the cardio-vascular system; Pharmaceutical preparations for the prevention and treatment of disorders of the metabolic system, namely, diabetes, bulimia nervosa, anorexia, obesity, hypothyroidism and hypoglycemia; Pharmaceutical preparations for the prevention and treatment of disorders of the respiratory system; Pharmaceutical preparations for the prevention and treatment of disorders of the musculo-skeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, bone fractures, sprains and cartilage injuries; Pharmaceutical preparations for the prevention and treatment of disorders of the genitourinary system, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; Pharmaceutical preparations for the treatment of inflammatory disorders, namely, inflammation of alimentary canal bowel diseases and inflammatory connective tissue diseases; Pharmaceutical preparations for use in dermatology, namely, for the treatment of dermatitis, skin pigmentation diseases, eczema, acne and psoriasis; Pharmaceutical preparations for use in oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, namely, bacterial skin infections, bacterial enteritis, pneumonia, respiratory tract infections, infections of the alimentary canal, infections of the eyes, nose, ears and mouth and ulcers; and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections and skin infections; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, a blood clotting aid and a drug delivery system comprising polymerbased oral tablets for the continuous release of a wide variety of therapeutic agents, for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymerbased oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations against dry skin caused by pregnancy; Pharmaceutical preparations for chloasma; Pharmaceutical preparations for hydrating the skin during pregnancy; Pharmaceutical preparations for pregnancy blemishes; Pharmaceutical preparations for preventing skin blemishes during pregnancy; Pharmaceutical preparations to prevent stretch marks; Pharmaceutical preparations to prevent swelling in the legs; Pharmaceutical preparations for ophthalmological use; Pharmaceutical preparations for the treatment of dermatitis and skin pigmentation diseases for animals; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for the treatment of joint disease; Pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), and for the treatment of infectious diseases, namely, respiratory infections, eye infections and skin infections; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Preparation for the relief of pain; Preparations for the treatment of asthma
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Opium alkaloid preparations for the treatment of chronic pain; Pharmaceutical anti-allergic preparations; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, spinal cord diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases and intermittent claudication; Pharmaceutical preparations for the treatment of gastro-intestinal diseases including diarrhea; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for skin care, namely, creams, gels, lotions, body washes, antibiotic creams and ointments for the treatment of dry skin, Psoriasis, eczema, acne and allergies; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease and intermittent claudication; Pharmaceutical preparations for the prevention and treatment of disorders of the immune system, namely, autoimmune diseases and immunologic deficiency syndromes; Pharmaceutical preparations for the prevention and treatment of disorders of the cardio-vascular system; Pharmaceutical preparations for the prevention and treatment of disorders of the metabolic system, namely, diabetes, bulimia nervosa, anorexia, obesity, hypothyroidism and hypoglycemia; Pharmaceutical preparations for the prevention and treatment of disorders of the respiratory system; Pharmaceutical preparations for the prevention and treatment of disorders of the musculo-skeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, bone fractures, sprains and cartilage injuries; Pharmaceutical preparations for the prevention and treatment of disorders of the genitourinary system, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; Pharmaceutical preparations for the treatment of inflammatory disorders, namely, inflammation of alimentary canal bowel diseases and inflammatory connective tissue diseases; Pharmaceutical preparations for use in dermatology, namely, for the treatment of dermatitis, skin pigmentation diseases, eczema, acne and psoriasis; Pharmaceutical preparations for use in oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, namely, bacterial skin infections, bacterial enteritis, pneumonia, respiratory tract infections, infections of the alimentary canal, infections of the eyes, nose, ears and mouth and ulcers; and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections and skin infections; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, a blood clotting aid and a drug delivery system comprising polymerbased oral tablets for the continuous release of a wide variety of therapeutic agents, for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymerbased oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations against dry skin caused by pregnancy; Pharmaceutical preparations for chloasma; Pharmaceutical preparations for hydrating the skin during pregnancy; Pharmaceutical preparations for pregnancy blemishes; Pharmaceutical preparations for preventing skin blemishes during pregnancy; Pharmaceutical preparations to prevent stretch marks; Pharmaceutical preparations to prevent swelling in the legs; Pharmaceutical preparations for ophthalmological use; Pharmaceutical preparations for the treatment of dermatitis and skin pigmentation diseases for animals; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for the treatment of joint disease; Pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), and for the treatment of infectious diseases, namely, respiratory infections, eye infections and skin infections; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Preparation for the relief of pain; Preparations for the treatment of asthma.
79.
PROCESS FOR THE PRODUCTION OF PROANTHOCYANIDIN POLYMERIC COMPOSITION
The present patent application relates to a process for the isolation and purification of a proanthocyanidin polymeric composition, the composition having high purity and being suitable for use in pharmaceutically effective formulations. In particular, the invention relates to a process for the production of Crofelemer suitable for pharmaceutical formulations and having a level of purity and concentration which enable it to be used in a therapeutically effective manner.
The present invention relates to a pharmaceutical powder composition for inhalation comprising an active ingredient and a pharmaceutically acceptable carrier, process for preparing such composition, and its use for the treatment of respiratory disorder in a subject.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 9/72 - Préparations médicinales caractérisées par un aspect particulier à fumer ou inhaler
The present invention relates to pharmaceutical composition for oral administration comprising prasugrel or its salt and triflusal, as well as to a process for preparation of such composition, and use of such composition for treating a platelet aggregation disorder in a subject.
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p. ex. ticlopidine
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
Processes for producing pharmaceutical compositions containing a proanthocyanidin polymer useful for the treatment and prevention of various conditions are provided. The invention specifically relates to processes for producing pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a process for producing proanthocyanidin polymer compositions which achieve concentrations and purities useful for addition to pharmaceutically effective formulations.
The present invention refers to a topical, preferably anhydrous pharmaceutical formulation comprising voriconazole or its pharmaceutically acceptable salt and a carrier. The formulation is prepared by dispersing voriconazole in a solvent, separately melting the excipients, mixing the dispersion with the molten excipients, homogenizing said mixture and then cooling it.
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40° C. and relative humidity of about 75% for a period of at least 3 months. Particularly, the present invention relates to stable fixed dose topical formulations comprising therapeutically effective amounts of (a) adapalene-containing microspheres and (b) clindamycin, a process for their preparation thereof and their use for the treatment of acne.
A61K 8/368 - Acides carboxyliquesLeurs sels ou anhydrides dans lesquels le groupe carboxyle est directement lié aux atomes de carbone du cycle aromatique
The present invention provides TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPAl (Transient Receptor Potential subfamily A, member 1) modulators. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPAl.
C07D 209/48 - Iso-indolesIso-indoles hydrogénés avec des atomes d'oxygène en positions 1 et 3, p. ex. phtalimide
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
86.
TOPICAL FORMULATION COMPRISING ADAPALENE MICROSPHERES AND CLINDAMYCIN
The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40 °C and relative humidity of about 75 % for a period of at least 3 months. Particularly, the present invention relates to stable fixed dose topical formulations comprising therapeutically effective amounts of (a) adapalene-containing microspheres and (b) clindamycin, a process for their preparation thereof and their use for the treatment of acne.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/7042 - Composés ayant des radicaux saccharide et des hétérocycles
The present invention relates to a fixed dose topical pharmaceutical formulation comprising minoxidil and aminexil, processes for preparing such formulation and their method of use for the treatment of alopecia in human.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
89.
TOPICAL COMPOSITION COMPRISING HALOBETASOL AND SALICYLIC ACID
The present invention relates to topical pharmaceutical compositions, their uses an methods of manufacturing. Specifically, the present invention relates to topical composition comprising combination of halobetasol and salicylic acid.
A61K 31/569 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone substitués en position 17 alpha, p. ex. œthistérone
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
The present invention relates to topical compositions comprising arbutin, corticosteroid, retinoid and optionally a sun protection factor (SPF). The present invention also relates to a process of preparation of said topical compositions.
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
A61K 31/07 - Composés du rétinol, p. ex. vitamine A
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
92.
TOPICAL PHARMACEUTICAL COMPOSITION FOR THE COMBINATION OF FUSIDIC ACID AND A CORTICOSTEROID
The present invention relates to topical compositions comprising combination of mometasone furoate and fusidic acid. The present invention also relates to use of topical combinations of mometasone furoate and fusidic acid for prevention and treatment of dermal infections. The present invention also relates to topical compositions comprising Halobetasol propionate and fusidic acid and their use for prevention and treatment of dermal conditions.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
The present invention relates to a topical pharmaceutical composition comprising mupirocin and beclomethasone, processes for its preparation, and its use in the treatment of infected dermatoses caused by bacteria susceptible to mupirocin and in the treatment or prevention of secondary bacterial infections in patients of steroid responsive dermatoses.
The present invention relates to topical formulations containing sertaconazole or its pharmaceutically acceptable salts as active ingredient. As adjuvants the formulations contain at least one stiffening agent, namely a fatty alcohol and/or its esters, at least one emulsifier and at least one emollient.
The present invention provides process for the preparation of novel intermediates of (S)-Pregabalin. The present invention also provides process for the preparation of (S)-Pregabalin or a pharmaceutically acceptable salt or solvate thereof using the intermediates.
C07C 227/12 - Formation de groupes amino et carboxyle
C07C 229/08 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un seul groupe amino et un seul groupe carboxyle liés au squelette carboné l'atome d'azote du groupe amino étant lié de plus à des atomes d'hydrogène
C07D 319/06 - Dioxanes-1, 3Dioxanes-1, 3 hydrogénés non condensés avec d'autres cycles
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
97.
PHARMACEUTICAL COMPOSITION COMPRISING ROSUVASTATIN OR PHARMACEUTICALLY ACCEPATBLE SALTS THEREOF
The present invention relates generally to a pharmaceutical compositions comprising an HMG Co-A reductase inhibitor e.g.: rosuvastatin or pharmaceutically acceptable salts thereof and inorganic salt of a monovalent cation.
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
The present invention generally relates to a novel pharmaceutical composition containing Dexibuprofen and Paracetamol in the form of soft gelatin capsule dosage form and process for preparing the same.
The present invention provides a process for the preparation of the rosuvastatin intermediates and their conversion to rosuvastatin or its pharmaceutically acceptable salts thereof.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
